Reading CMPX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CMPX free→Reading CMPX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CMPX free→QuarterlyIQ Insights · CMPX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: May 5, 2026 By: /s/ Neil Lerner Neil Lerner Chief Accounting Officer
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: March 5, 2026 By: /s/ Neil Lerner Neil Lerner Chief Accounting Officer
Results of Operations and Financial Condition. The information contained in
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: November 5, 2025 By: /s/ Neil Lerner Neil Lerner Chief Accounting Officer
Entry into a Material Definitive Agreement On August 12, 2025, Compass Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Piper Sandler & Co., and Guggenheim Securities, LLC, as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 33,290,000 shares (the “Firm Shares”) of its common stock, par value $0.00…
99.2 Corporate presentation - Earnings Call August 11, 2025 99.3 Corporate presentation of Compass Therapeutics, Inc. dated August 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: August 11, 2025 By: /s/ Neil Lerner Neil Lerner Chief…
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: May 8, 2025 By: /s/ Neil Lerner Neil Lerner Chief Accounting Officer
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.